IP Library Granted Patent US 9,889,195
Granted Patent B2
US 9,889,195 · App. 14/602,778 · Granted Feb 13, 2018

Immunogenic composition and uses thereof

Inventors: David Charles Jackson (North Balwyn, AU); Weiguang Zeng (Kensington, AU); Brendon Yew Loong Chua (Heidelberg Heights, AU)
Assignee: INNAVAC PTY LTD
A61K39/39A61K31/23A61K38/03A61K38/38A61K45/06C07K2/00C07K14/77A61K2039/55516A61K2039/6018
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,889,195
App. No.
14/602,778
Granted
Feb 13, 2018
Kind
B2
Abstract

The present invention provides an immunogenic composition comprising an antigen and a dendritic cell targeting component. A charged group is covalently attached to a dendritic cell ligand and is electrostatically associated with the dendritic cell targeting component.

Claims (5)

1. An immunogenic composition comprising a complex of a polypeptide antigen and a dendritic cell targeting component, wherein the polypeptide antigen comprises a negatively charged region, wherein the negatively charged region of the polypeptide antigen electrostatically associates with the dendritic cell targeting component, thereby enabling formation of the complex,

wherein the dendritic cell targeting component comprises:

and wherein Pam2Cys refers to dipalmitoyl-S-glycerylcysteine.

2. The immunogenic composition according to claim 1 , wherein the polypeptide antigen has an overall negative charge.

3. The immunogenic composition according to claim 1 , wherein the polypeptide antigen is associated with the dendritic cell targeting component by electrostatic interaction only.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2022
From: AXELIA ONCOLOGY PTY LTD
To: ENA RESPIRATORY PTY LTD
Reel/Frame 060974/0801 →
CHANGE OF NAME Recorded Aug 31, 2022
From: ENA THERAPEUTICS PTY LTD
To: AXELIA ONCOLOGY PTY LTD
Reel/Frame 060949/0760 →
CHANGE OF NAME Recorded Aug 14, 2018
From: INNAVAC PTY LTD
To: ENA THERAPEUTICS PTY LTD
Reel/Frame 046804/0400 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2017
From: THE UNIVERSITY OF MELBOURNE
To: INNAVAC PTY LTD
Reel/Frame 043943/0693 →
Continuity (4)
Continuation 13268069 · Oct 7, 2011
Continuation PCTAU2009000469 · Apr 16, 2009
Continuation In Part PCTAU2009000446 · Apr 9, 2009
Related Publication 20150150966A1 · Jun 4, 2015